Vebreltinib trials for Non-Small-Cell Lung Cancer

All Vebreltinib trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Vebreltinib for Non-Small-Cell Lung Cancer

• Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
  NCT07655622 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
  NCT06574347 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
  NCT06343064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Vebreltinib for Non-Small-Cell Lung Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.